Open Access
Issue
Med Buccale Chir Buccale
Volume 19, Number 2, avril 2013
Page(s) 91 - 99
Section Mise au point / Literature review
DOI https://doi.org/10.1051/mbcb/2012052
Published online 18 January 2013
  1. Smith A, Kressley A, Saif MW. Oral osteonecrosis associated with the use of zoledronic acid: first case with advanced pancreatic cancer and bone metastasis. JOP 2009;10:212-4. [PubMed] [Google Scholar]
  2. Advisory task force on bisphosphonate-related osteonecrosis of the jaws, American association of oral and maxillofacial surgeons. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76. [CrossRef] [PubMed] [Google Scholar]
  3. Rayman S, Almas K, Dincer E. Bisphosphonate-related jaw necrosis: a team approach management and prevention. Int J Dent Hyg 2009;7:90-5. [CrossRef] [PubMed] [Google Scholar]
  4. Marx RE. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws. History, etiology, prevention, and treatment, 2nd ed. Quintessence Publishing Co, Inc, Chicago, 2007. [Google Scholar]
  5. Salino S, Bodard AG, Timour Q. Ostéoradionécrose et ostéonécrose des maxillaires aux bisphosphonates. Encyc Med Chir Stomatol 28-865-A-10. Elsevier Masson SAS, Paris, 2010. [Google Scholar]
  6. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-11. [CrossRef] [PubMed] [Google Scholar]
  7. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. [CrossRef] [PubMed] [Google Scholar]
  8. Agence Nationale de Sécurité des Médicaments et des produits de sante (ANSM). Lettres aux professionnels de santé. Recommandations sur la prise en charge bucco-dentaire des patients traités par bisphosphonates. 18 décembre 2007. Accessible le 21 septembre 2012 sur http://www.ansm.sante.fr/content/download/11694/140950/version/2/file/lp071203.pdf [Google Scholar]
  9. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons (AAOMS) position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. J Oral Maxillofac Surg 2009;67 (suppl 1):2-12. [CrossRef] [Google Scholar]
  10. Abi Najm S, Lesclous P, Lombardi T, Bouzouita I, Carrel JP, Samson J. Ostéonécrose des maxillaires due aux bisphosphonates (2ème partie) : expérience genevoise. Med Buccale Chir Buccale 2008;14:63-84. [CrossRef] [EDP Sciences] [Google Scholar]
  11. Savoldelli C, Le Page F, Santini J, Scortecci G, Odin G. Ostéonécrose maxillaire sous bisphosphonates et implants dentaires. Rev Stomatol Chir Maxillofac 2007;108:555-8. [CrossRef] [PubMed] [Google Scholar]
  12. Lesclous P, Abi Najm S, Samson J. Bisphosphonates et pratique bucco-dentaire. Rev Odonto-Stomatol 2011;40:173-91. [Google Scholar]
  13. Walter C, Al-Nawas B, Frickhofen N, Gamm H, Beck J, Reinsch L, Blum C, Grötz KA, Wagner W. Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 2010;6:11. [CrossRef] [PubMed] [Google Scholar]
  14. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkei G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-69. [CrossRef] [PubMed] [Google Scholar]
  15. Nalliah R. Prevalence of bisphosphonate-related osteonecrosis in patients with cancer could be as high as 13,3 percent. J Am Dent Assoc 2012;143:170-1. [PubMed] [Google Scholar]
  16. Khan AA, Sandor GK, Dore E. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36:478-90. [CrossRef] [PubMed] [Google Scholar]
  17. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society of bone and mineral research. J Bone Miner Res 2007;22:1479-91. [CrossRef] [PubMed] [Google Scholar]
  18. Fleish H. Bisphosphonate: mechanisms of action. Endocr Rev 1998;19:80-100. [CrossRef] [PubMed] [Google Scholar]
  19. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008;66:767-75. [CrossRef] [PubMed] [Google Scholar]
  20. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonate: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34. [CrossRef] [PubMed] [Google Scholar]
  21. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000;15:613-20. [CrossRef] [PubMed] [Google Scholar]
  22. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induces exposed bone (osteonecrosis/osteoporosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75. [CrossRef] [PubMed] [Google Scholar]
  23. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41:318-20. [CrossRef] [PubMed] [Google Scholar]
  24. Reskaa AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001;59:193-202. [PubMed] [Google Scholar]
  25. Brozoski MA, Traina AA, Zindel Deboni MC, Marques MM, Naclério-Homem MG. Bisphosphonate-related osteonecrosis of the jaw. Rev Bras Reumatol 2012;52:265-70. [CrossRef] [PubMed] [Google Scholar]
  26. American Dental Association. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006;137:1144-50. [PubMed] [Google Scholar]
  27. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S; American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57. Epub 2003 Sep 8. Erratum in: J Clin Oncol 2004;22:1351. [CrossRef] [PubMed] [Google Scholar]
  28. Erkan M, Bilgi O, Multluoglu M, Uzun G. Bisphosphonate-related osteonecrosis of the jaw in cancer patients and hyperbaric oxygen therapy. JOP. J Pancreas 2009;10:579-80. [Google Scholar]
  29. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010;136:1117-24. [CrossRef] [PubMed] [Google Scholar]
  30. Vescovi P, Merigo E, Manfredi M. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. Photomed Laser Surg 2008;26:37-46. [CrossRef] [PubMed] [Google Scholar]
  31. Vescovi P, Manfredi M, Merigo E, Meleti M, Fornaini C, Rocca JP, Nammour S. Surgical approach with ER:YAG Laser on osteonecrosis of the jaws (ONJ in patients under bisphosphonate therapy (BPT). Lasers Med Sci 2010;25:101-13. [CrossRef] [PubMed] [Google Scholar]
  32. Antonini F, Pereira CC, Perante EV, Azambuja FG. Management of osteonecrosis of the jaws in patients with history of bisphoshonate therapy. J Craniofac Surg 2010;21:1962-6. [CrossRef] [PubMed] [Google Scholar]
  33. Lee YS, David T, Nishime M. Use of platelet-rich plasma in the management of oral bisphonsphonate associated osteonecrosis of the jaw: a report of two cases. J Oral Implantol 2007;26:371-82 [CrossRef] [Google Scholar]
  34. Eppley BL, Pietrzak WS, Blanton M. Platelet-rich plasma: a review of biology and applications in plastic surgery. Plast Reconstr Surg 2006;118:e147-59. [CrossRef] [PubMed] [Google Scholar]
  35. Agrillo A, Ungari C, Filiaci F, Priore P, Iannetti G. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg 2007;18:1071-5. [CrossRef] [PubMed] [Google Scholar]
  36. Gunepin M, Derache F, Cathelinaud O, Bladé JS, Risso JJ, Blatteau JE, Bédrune B, Hugon M, Rivière D. Intérêt de l’utilisation de l’oxygénothérapie hyperbare en prévention de l’échec implantaire chez le patient irradié. Med Buccale Chir Buccale 2012;18:143-53. [CrossRef] [EDP Sciences] [Google Scholar]
  37. Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(suppl 5):96-106. [CrossRef] [PubMed] [Google Scholar]
  38. Sawai T, Noomi A, Johansson CB, Sennerby L, Ozeki K, Ozeki K, Takahashi H, Albrektsson T, Ueda M. The effect of hyperbaric oxygen treatment on bone tissue reactions to c.p. titanium implants placed in free autogenous bone grafts. A histomorphometric study in the rabbit mandibule. Clin Oral Implants Res 1998;9:384-97. [CrossRef] [Google Scholar]
  39. Tuncay OC, Ho D, Barker MK. Oxygen tension regulates osteoblast function. Am J Orthod Dentofac Orthop 1994;105:457-63. [CrossRef] [PubMed] [Google Scholar]
  40. Granström G. Hyperbaric oxygen as a stimulator of osseointegration. Adv Otorhinolaryngol 1998;54:33-49. [PubMed] [Google Scholar]
  41. Johnsson AA, Sawaii T, Jacobsson M, Granström G, Turesson I. A histomorphometric study of bone reactions to titanium implants in irradiated bone and the effect of hyperbaric oxygen treatment. Int J Oral Maxillofac Implants 1999;14:699-706. [PubMed] [Google Scholar]
  42. Marx RE, Johnson RP, Kline SN. Prevention of osteoradionecrosis: a random-ized prospective clinical trial of hyperbaric oxygen versus penicillin. J Am Dent Assoc 1985;111:49-54. [PubMed] [Google Scholar]
  43. Sutthavong S, Jansisyanont P, Boonyopastham N. Oral health care in head and neck cancer. J Med Assoc Thai 2005; 88 (suppl 3): S339-53. [Google Scholar]
  44. Haute Autorité de Santé (HAS) – service d’évaluation des actes professionnels. Oxygénothérapie hyperbare – janvier 2007 accessible sur http://www.has-sante.fr/portail/upload/docs/application/pdf/rapport_oxygenotherapie.pdf le 15 septembre 2012. [Google Scholar]
  45. Okubo Y, Bessho K, Fujimura K, Kusumoto K, Ogawa Y, Iizuka T. Effect of hyperbaric oxygenation on bone induced by recombinant human bone morphogenetic protein-2. Br J Oral Maxillofac Surg 2001;39:91-5. [CrossRef] [PubMed] [Google Scholar]
  46. Ueng SW, Lee SS, Lin SS, Wang CR, Liu SJ, Yang HF, Tai CL, Shih CH. Bone healing of tibia lengthening is enhanced by hyperbaric oxygen therapy: a study of bone mineral density and torsional strength on rabbits. J Traum 1998;44:676-81. [CrossRef] [PubMed] [Google Scholar]
  47. Chen CE, Ko JY, Fu TH, Wang CJ. Results of chronic osteomyelitis of the femur treated with hyperbaric oxygen: a preliminary report. Chang Gung Med J 2004;27:91-7. [PubMed] [Google Scholar]
  48. Tripathi KK, Moorthy A, Karai RC, Rao G, Gosh OC. Effet of hyperbaric oxygen on bone healing after enucleation of mandibular cysts: a modified case-control study. Diving Hyperb Med 2011;41:195-201. [PubMed] [Google Scholar]
  49. Strauss MB, Bryant B. Hyperbaric oxygen. Orthopedics 2002;25:303-10. [PubMed] [Google Scholar]
  50. Ruggiero SL, Woo SB. Bisphosphonate-related osteonecrosis of the jaws. Dent Clin North Am 2008;52:111-28. [CrossRef] [PubMed] [Google Scholar]
  51. Wong YK, Cheng JC. Prévention et traitement des ostéonécroses dues aux bisphosphonates : deux cas cliniques. Titane 2009;6:42-7. [Google Scholar]
  52. Freiberger J, Padilla-Burgos R, Chhoeu A, Kraft KH, Boneta O, Moon RE, Piantadosi CA. Hyperbaric oxygen treatment and bisphosphonate-induces osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007;65:1321-7. [CrossRef] [PubMed] [Google Scholar]
  53. Mariotti A. Bisphosphonate and osteonecrosis of the jaws. J Dent Educ 2008;72:919-29. [PubMed] [Google Scholar]
  54. Shirota T, Nakamura A, Matsui Y, Hatori M, Nakamura M, Shintani S. Bisphosphonate-related osteonecrosis of the jaw around dental implants in the maxilla: report of a case. Clin Oral Implants Res 2009;20:1402-8. [CrossRef] [PubMed] [Google Scholar]
  55. Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, Delaroudis S. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol 2007;28:158-63. [CrossRef] [Google Scholar]
  56. Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, Russo PA, Kreusch T. “Bis-phossy jaws” - high and low risk factors for bisphosphonate-induces osteonecrosis of the jaw. J Craniomaxillofac Surg 2008;36:95-103. [CrossRef] [PubMed] [Google Scholar]
  57. Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004;117:440-1. [CrossRef] [PubMed] [Google Scholar]
  58. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ, Scully C. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3. [CrossRef] [PubMed] [Google Scholar]
  59. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, PiniPrato G. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32:1123-8. [CrossRef] [PubMed] [Google Scholar]
  60. Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R, Tomich C. Osteonecrosis of the mandibule or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006;116:115-20. [CrossRef] [PubMed] [Google Scholar]
  61. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-41. [CrossRef] [PubMed] [Google Scholar]
  62. Chhoeu AH, Longphre JM, Kraft KH, Boneta O, Conard JL, Freiberger JJ. A case series of hyperbaric oxygen treatment for non-radiation induced osteonecrosis of the jaw. J Oral Maxillofac Surg 2006;64:80-1. [CrossRef] [Google Scholar]
  63. Hugentobler M, Richter M. Proposition d’un algorithme de prise en charge médico-dentaire pour les patients traités par bisphosphonates. Rev Stomatol Chir Maxillofac 2006;107;441-4. [CrossRef] [PubMed] [Google Scholar]
  64. Magremanne M, Aubert C, Vervaet C, Dufrasne L, Evrard L, Daelemans P. Ostéochimionécrose maxillo-mandibulaire et bisphosphonates. A propos d’un cas et revue de la littérature. Rev Med Brux 2007;28:453-8. [Google Scholar]
  65. Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofac Surg Clin North Am 2007;19:487-98. [CrossRef] [PubMed] [Google Scholar]
  66. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTx testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410. [CrossRef] [PubMed] [Google Scholar]
  67. King AE, Umland EM. Osteonecrosis of the jaw in patient receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008;28:667-77. [CrossRef] [PubMed] [Google Scholar]
  68. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29:1548-58. [CrossRef] [PubMed] [Google Scholar]
  69. Estilo CS, Van Poznak CH, Williams T, Evtimovska E, Tkach L, Halpern JL, Tunick SL, Huryn JM. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study. J Clin Oncol 2004;22(suppl 14s):8088. [Google Scholar]
  70. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risks factors. J Clin Oncol 2006;24:945-52. [CrossRef] [PubMed] [Google Scholar]
  71. Woeller A, Gering A, Brix M, Bettega G, Lebeau J. Ostéonécrose des maxillaires sous bisphosphonates : cinq cas. Rev Stomatol Chir Maxillofac 200;107:417-22. [CrossRef] [PubMed] [Google Scholar]
  72. Pautke C, Kreutzer K, Weitz J, Knödler M, Münzel D, Wexel G, Otto S, Hapfelmeier A, Stürzenbaum S, Tischer T. Bisphosphonate related osteonecrosis of the jaw: a minipig large animal model. Bone 2012;51:592-9. [CrossRef] [PubMed] [Google Scholar]
  73. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol. 2007;4:42-55. [CrossRef] [PubMed] [Google Scholar]
  74. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos, E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risks factors. J Clin Oncol 2005;23:8580-7. [CrossRef] [PubMed] [Google Scholar]
  75. Hoff AO, Toth BB, Altundag K. Osteonecrosis of the jaw in patients receiving intravenous BP therapy. J Clin Oncol 2006;24:8528. [Google Scholar]
  76. Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphposphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61. [CrossRef] [PubMed] [Google Scholar]
  77. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl Med 2005;353:99-102. [CrossRef] [Google Scholar]
  78. Bozas G, Roy A, Ramasamy V, Maraveyas A. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. Onkologie 2010;33:321-3. [CrossRef] [PubMed] [Google Scholar]
  79. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-36. [CrossRef] [PubMed] [Google Scholar]
  80. Jadu F, Lee L, Pharoah M, Reeve D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007;18:2015-19. [CrossRef] [PubMed] [Google Scholar]
  81. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009;122 (suppl 2):S33-45. [CrossRef] [Google Scholar]
  82. Vescovi P, Nammour S. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) therapy. A critical review. Minerva Stomatol 2010;59:183-203, 204-13. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.